BioTech IP Review

Assignee: Inmagene Biopharmaceuticals Hangzhou Co. Ltd.; Inmagene Pte. Ltd.
Publication Number: WO2025185555A1
Filing Date: March 3, 2025 (Application PCT/CN2025/080184)
Publication Date: September 12, 2025
Priority Date: March 4, 2024
Status: Pending international (PCT) application (not yet granted)

---

What This Patent Covers

This international patent application describes pharmaceutical compositions and dosage forms containing monoclonal antibodies that target the OX40 receptor, along with their therapeutic uses. Specifically:

• Anti‑OX40 antibody formulations: The application focuses on compositions containing anti‑OX40 monoclonal antibodies — engineered biologics that bind the OX40 receptor.
• Therapeutic uses: It covers the use of these compositions for treating diseases associated with OX40 signaling, particularly immunological and inflammatory conditions where OX40/OX40L interactions drive pathology (e.g., atopic dermatitis, alopecia areata and other T‑cell mediated diseases).
• Formulation details: The application includes aspects like pharmaceutical preparations, dosages and methods of administering these antibody compositions to patients as part of a treatment regimen.

In practical terms, this application directly supports and protects the technological basis for Inmagene’s lead clinical‑stage asset, IMG‑007, which is a non‑depleting, extended‑half‑life anti‑OX40 monoclonal antibody currently being advanced in Phase 2b development for moderate‑to‑severe atopic dermatitis — one of its most attractive near‑term commercial opportunities.

---

Why This Is Important

• Directly tied to lead therapeutic: Anti‑OX40 antibodies like IMG‑007 are central to the company’s pipeline and potential future revenue. Protecting compositions and use of these antibodies strengthens exclusivity around its lead biologic program.
• Broad therapeutic scope: OX40 is a key immune checkpoint involved in T‑cell activation and survival; compounds targeting it may be useful across several significant immunological and inflammatory diseases.
• Global protection strategy: Although this is an international (PCT) application — not yet a granted U.S. patent — it lays the groundwork for subsequent national phase filings in major markets (e.g., U.S., EU, Japan), which could form the basis of future granted rights.
• Supports clinical and commercial value: The patent application aligns with the company’s strategic progression of IMG‑007 through late‑stage clinical studies and eventual commercialization planning, making it a core IP pillar for investor and partner confidence.